Skip to main content

Table 3 Odds ratios for CMH in adjusted* analyses

From: Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion

 

LSC n = 900

PLuSS n = 490

Combined n = 1390

Exposure variable

OR

(95 % CL)

p value

OR

(95 % CL)

p value

OR

(95 % CL)

p value

Total methylation

1.09***

(1.02, 1.17)

0.014

1.15

(1.03, 1.29)

0.014

1.11

(1.04, 1.18)

0.001**

SULF2

1.68

(1.23, 2.30)

0.001**

2.14

(1.38, 3.31)

0.001**

1.79

(1.39, 2.31)

<.0001**

p16

1.43

(0.97, 2.11)

0.067

1.69

(1.01, 2.83)

0.045

1.54

(1.14, 2.10)

0.006

JPH3

1.45

(1.04, 2.03)

0.031

1.70

(0.83, 3.48)

0.149

1.53

(1.13, 2.08)

0.006

PCDH20

1.40

(1.03, 1.90)

0.033

1.73

(1.10, 2.73)

0.018

1.47

(1.14, 1.90)

0.003**

  1. Each row represents a separate adjusted model.
  2. LSC: CMH (n = 311) and no CMH (n = 589); PLuSS CMH (n = 140) and no CMH (n = 350).
  3. *Additional adjustors include age, sex, education, COPD, current smoking, pack years, and cohort (for combined analysis); CMH as outcome.
  4. **Bonferroni adjusted significance threshold is p < 0.0042.
  5. ***Represents the odds ratio increase for each additional gene methylated.